论文部分内容阅读
人们通常用静脉输入硫酸镁抑制宫缩防止早产。但预防早产成功与血清镁浓度之间的关系尚不清楚。为进一步评估这一问题,作者回顾分析了1986年4月至1987年7月间83例早产病人,共101次早产,以探讨宫缩抑制、预防早产成功是否与血清镁离子浓度有关。患者孕周为20～36周,符合下述早产标准:20分钟内4次正规宫缩或60分钟内8次正规宫缩和/或进行性宫颈扩张或宫颈扩张2cm,和/或至少50%宫颈管消失。已破膜,羊膜炎或前置胎盘患者除外。首次剂量为4或6g硫酸镁静脉推注,30分钟以上推完。维持量为2～3g/hr,静滴;以血清镁浓度监测毒性反应。经2g/hr硫酸镁治疗后若仍有明显
People often use intravenous magnesium sulfate inhibition of contractions to prevent premature birth. However, the relationship between the success of prevention of preterm birth and serum magnesium concentration is not clear. To further assess this issue, the authors retrospective analysis of 83 cases of premature labor between April 1986 and July 1987, a total of 101 premature births to explore the impact of contractions inhibition, prevention of preterm birth and serum magnesium concentration. Patients with gestational weeks of 20 to 36 weeks meet the following preterm birth criteria: 4 times within 20 minutes of normal contractions within 60 minutes or 8 times normal contractions and / or progressive cervical dilatation or cervical dilatation 2cm, and / or at least 50% Cervical tube disappears. Ruptured membrane, amniotic inflammation or placenta previa except. The first dose of 4 or 6g intravenous injection of magnesium sulfate, push over 30 minutes. Maintenance volume of 2 ~ 3g / hr, intravenous infusion; serum magnesium concentration monitoring toxicity. After 2g / hr magnesium sulfate treatment if there is still significant